Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dianthus Therapeutics, Inc. (DNTH : NSDQ)

• Company Description    Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $41.21 Daily Weekly Monthly 20 Day Moving Average: 592,393 shares Shares Outstanding: 42.88 (millions) Market Capitalization: $1,766.92 (millions) Beta: 1.55 52 Week High: $45.46 52 Week Low: $13.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.83% -7.67% 12 Week 18.59% 16.68% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 Times Square 43rd Floor - New York,NY 10036 USA ph: 929-999-4055 fax: - ir@dianthustx.com http://www.dianthustx.com

• General Corporate Information    Officers Marino Garcia - President; Chief Executive Officer and Director Alison F. Lawton - Chairman Ryan Savitz - Chief Financial Officer and Chief Business Officer Edward Carr - Chief Accounting Officer Sujay Kango - Director Peer Information Dianthus Therapeutics, Inc. (CORR.) Dianthus Therapeutics, Inc. (RSPI) Dianthus Therapeutics, Inc. (CGXP) Dianthus Therapeutics, Inc. (BGEN) Dianthus Therapeutics, Inc. (GTBP) Dianthus Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 252828108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 42.88 Most Recent Split Date: 9.00 (0.06:1) Beta: 1.55 Market Capitalization: $1,766.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.23 Price/Cash Flow: - Price / Sales: 574.23 EPS Growth vs. Year Ago Period: -31.08% vs. Previous Quarter: -10.23% Sales Growth vs. Year Ago Period: -81.77% vs. Previous Quarter: 105.18% ROE 12/31/25 - - 09/30/25 - -33.02 06/30/25 - -34.72 ROA 12/31/25 - - 09/30/25 - -31.08 06/30/25 - -32.72 Current Ratio 12/31/25 - - 09/30/25 - 17.35 06/30/25 - 13.12 Quick Ratio 12/31/25 - - 09/30/25 - 17.35 06/30/25 - 13.12 Operating Margin 12/31/25 - - 09/30/25 - -4,106.04 06/30/25 - -2,364.56 Net Margin 12/31/25 - - 09/30/25 - -4,106.04 06/30/25 - -2,364.56 Pre-Tax Margin 12/31/25 - - 09/30/25 - -4,106.11 06/30/25 - -2,364.60 Book Value 12/31/25 - - 09/30/25 - 12.75 06/30/25 - 9.42 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©